Sleep Restriction
Conditions
Keywords
Sleep Restriction, Alertness, Performance, Neuroinflammation, Biomarker
Brief summary
Chronic sleep restriction is ubiquitous in both the general population and the military. The deleterious effects of sleep loss on human alertness and cognitive performance have been documented in numerous studies dating back to the nineteenth century. Over the past decade, evidence has emerged indicating that chronic sleep restriction may also precipitate deleterious, long lasting neuropathological changes in the brain. The purpose of this study is to determine neuropathological effects of sleep restriction and identify physiological mechanisms that correlate with sleep loss-induced performance impairment.
Interventions
DRUG[11C]ER176
Brain PET with \[11C\]ER176. \[11C\]ER176 is a PET ligand that images TSPO.
Sponsors
National Institute of Mental Health (NIMH)
National Intrepid Center of Excellence
Walter Reed Army Institute of Research (WRAIR)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* Ages 18 to 39 (inclusive) * A body mass index (BMI) below 30. * Weigh at least 140 lbs * Females must not be pregnant or nursing, and must be on some form of birth control, if sexually active (e.g., oral contraceptive, condom, intrauterine device, etc.) * No history of sleeping problems such as insomnia or sleep apnea. * Test negative for alcohol, nicotine, illegal drugs, and not take certain medications. * Must not excessively consume alcohol or caffeine. * Active duty and Federal employees must be on leave during participation. * No history of heart disease (high blood pressure), neurologic disorder (such as seizures of epilepsy), liver disease, kidney disease, or metabolic disorder or diabetes. * No history of underlying acute or chronic pulmonary disease requiring daily inhaler use.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positron Emission Tomography (PET) based measurement of neuroinflammation | 3 Days | Positron Emission Tomography (PET) is the brain imaging method and \[11C\]ER176 is the PET radioligand providing an index of neuroinflammation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Psychomotor Vigilance Task (PVT) | 55 Days | Measure of cognitive performance |
| Actigraphy | 55 Days | Activity monitoring used to infer sleep-wake patterns |
| Polysomnographic measurements of sleep and wakefulness | 19 Days | Measure of various aspects of sleep and wakefulness |
Countries
United States
Outcome results
None listed